Skip to main content
Quantum Genomics logo

Quantum Genomics — Investor Relations & Filings

Ticker · ALQGC ISIN · FR0011648971 LEI · 969500TFCD8K9RPM9K97 PA Manufacturing
Open in API
Filings indexed 341 across all filing types
Latest filing 2016-01-20 Investor Presentation
Country FR France
Listing PA ALQGC

About Quantum Genomics

https://quantum-genomics.com/

Quantum Genomics is a biopharmaceutical company focused on developing a new class of medications for cardiovascular diseases with high unmet medical needs, such as difficult-to-treat or resistant hypertension and heart failure. The company's core research is based on a breakthrough therapeutic approach involving the inhibition of Brain Aminopeptidase A (BAPA). Its lead drug candidate, firibastat, is a first-in-class BAPA inhibitor designed to offer a novel treatment mechanism for managing these conditions.

Recent filings

Filing Released Lang Actions
Renforcement de la propriété intellectuelle de Quantum Genomics
Investor Presentation Classification · 98% confidence The document is a press release announcing the granting of a new patent (US Patent No. 9187418) protecting the industrial manufacturing process for the drug candidate QGC001 until 2031. This announcement relates directly to the company's intellectual property portfolio and its core assets. Among the provided categories, 'IP' (Intellectual Property) is the most specific fit for a patent grant announcement. It is not a general regulatory filing (RNS), an earnings release (ER), or a management change (MANG).
2016-01-20 French
Enhancement of Quantum Genomics' intellectual property
Investor Presentation Classification · 85% confidence The document is a short press release dated January 20th, 2016, announcing the approval of a new patent in the United States (and others in Mexico and Eurasia) related to the manufacturing process of their drug candidate QGC001. This announcement concerns the protection of intellectual property (IP) and is not a comprehensive financial report (like 10-K or IR), an earnings release (ER), or a management discussion (MDA). Since the core subject is the enhancement and protection of intellectual property rights, it best fits under the general category of corporate announcements that are not covered by more specific financial or governance codes. While 'IP' is listed as a category, the provided definitions do not explicitly list 'Intellectual Property Announcement' as a code. Given the options, this is a specific corporate update regarding assets/rights. Since there is no specific code for 'Intellectual Property Update' and it is not a standard regulatory filing like 10-K or a standard financial report, it falls best into the general 'Regulatory Filings' (RNS) as a miscellaneous regulatory/corporate announcement, or potentially 'LTR' if patents are viewed as legal assets, but RNS is the safer fallback for non-standard announcements. However, upon reviewing the definitions, there is no explicit 'IP' code, and 'LTR' is for 'Legal Proceedings Report' (lawsuits/regulatory actions). Since this is a positive announcement about securing a patent, it is a corporate update. Given the available codes, and the nature of the announcement being about a specific corporate asset protection, it is closest to a general regulatory/corporate announcement, which defaults to RNS.
2016-01-20 English
Bilan semestriel du contrat de liquidité au 31 décembre 2015
Regulatory Filings Classification · 99% confidence The document is titled "Bilan semestriel du contrat de liquidité au 31 décembre 2015" (Semi-annual statement of the liquidity contract as of December 31, 2015). It reports the status of a liquidity contract (likely a market-making or stabilization agreement) at a specific semi-annual date. This type of filing, which details the status of financial arrangements or specific operational metrics outside of standard periodic financial reports (like 10-K or IR), often falls under general regulatory announcements or specific financial updates. Since it is a report on a specific financial mechanism (liquidity contract) and not a full interim report (IR), earnings release (ER), or a standard capital change (CAP), it best fits the 'Regulatory Filings' (RNS) category as a specific, non-standard regulatory disclosure, or potentially a specialized financial update. Given the options, RNS is the most appropriate fallback for a specific, non-core financial disclosure like a liquidity contract statement. It is not a standard dividend notice, management change, or director dealing report. The length (1832 chars) suggests it is a direct announcement, not just a cover letter for a larger document.
2016-01-07 French
Recrutement de 100% des patients pour l'étude clinique de phase IIa dans l'hypertension artérielle
Regulatory Filings Classification · 95% confidence The document is titled "Communiqué de presse" (Press Release) and announces a specific operational milestone: the completion of patient recruitment for a Phase IIa clinical study for a drug candidate (QGC001) related to hypertension. It includes quotes from management (Medical Director) and provides contact information for investors and press. This type of announcement, focusing on clinical trial progress and operational updates rather than full financial results (ER) or comprehensive reports (10-K, IR), is best classified as a general regulatory announcement or press release that updates investors on company progress. Since it is not a formal financial report, a management discussion, or a specific capital event, it fits best under the general Regulatory Filings category (RNS) or potentially a specialized category if one existed for clinical updates. Given the provided definitions, RNS serves as the most appropriate fallback for significant, non-financial, operational news releases.
2016-01-05 French
Patient enrolment 100% completed for Phase IIa trial for high blood pressure
Regulatory Filings Classification · 95% confidence The document is a press release dated January 5th, 2016, announcing the completion of patient enrolment for a Phase IIa clinical trial for a drug candidate (QGC001) for high blood pressure. It details the status of the trial, quotes the Medical Director, and provides contact information. This type of announcement, focusing on operational milestones (like trial completion or initiation) rather than full financial results (ER/IR) or management changes (MANG), is typically classified as a general Regulatory Filing (RNS) or sometimes a specific operational update. Since there is no specific category for clinical trial updates, and it is not a formal financial report (10-K, IR, ER), the most appropriate general category is Regulatory Filings (RNS), as it is a public announcement of a significant operational event. Given the document is a press release detailing operational progress, it fits best under the general regulatory announcement category.
2016-01-05 English
Une nouvelle avancée pour Quantum Genomics dans le cadre de son partenariat en santé animale dans l'insuffisance cardiaque
Regulatory Filings Classification · 90% confidence The document is a press release ("Communiqué de presse") dated December 16, 2015, announcing an update regarding a partnership in animal health concerning heart failure treatment, specifically mentioning receiving a letter of intent and outlining upcoming investor events. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement concerning business development and future investor relations activities. Since it is a general corporate announcement that doesn't fit the specific categories like M&A (TAR), Capital (CAP), or Director's Dealing (DIRS), the most appropriate general category for corporate news updates that aren't formal financial reports is Regulatory Filings (RNS), which serves as a broad category for miscellaneous official announcements not covered elsewhere.
2015-12-16 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.